Carone, Marianna
Spalinger, Marianne R. http://orcid.org/0000-0003-4498-0058
Gaultney, Robert A.
Mezzenga, Raffaele http://orcid.org/0000-0002-5739-2610
Hlavačková, Kristýna
Mookhoek, Aart
Krebs, Philippe http://orcid.org/0000-0003-4918-6654
Rogler, Gerhard http://orcid.org/0000-0002-1733-9188
Luciani, Paola http://orcid.org/0000-0001-9664-0149
Aleandri, Simone http://orcid.org/0000-0001-7190-1605
Article History
Received: 28 October 2022
Accepted: 25 May 2023
First Online: 13 June 2023
Competing interests
: The authors M.C., M.R.S., R.A.G., R.M., K.H., A.M., P.K., P.L. and S.A. declare no competing interests. G.R. declares the following competing interests: consulting to Abbvie, Arena, Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher, Genentech, Gilead, Janssen, Lilly, MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions and Zeller; received speaker’s honoraria from Abbvie, Astra Zeneca, BMS, Celgene, FALK, Janssen, MSD, Pfizer, Phadia, Takeda, Tillots, UCB, Vifor and Zeller; received educational grants and research grants from Abbvie, Ardeypharm, Augurix, Calypso, FALK, Flamentera, MSD, Novartis, Pfizer, Roche, Takeda, Tillots, UCB and Zeller. Gerhard Rogler is cofounder and head of the scientific advisory board of PharmaBiome. The TIF-Gel technology has been patented. <i>Patent applicant:</i> University of Bern and University of Zurich. <i>Name of inventor(s):</i> Marianna Carone, Marianne R. Spalinger, Robert A. Gaultney, Philippe Krebs, Gerhard Rogler, Paola Luciani, Simone Aleandri. <i>Application number:</i> European Patent Application No 22197842.3 <i>Status of application:</i> The above application has been filed with the European Patent Office (EPO). Filing Date: 26.09.2022 <i>Specific aspect of manuscript covered in patent application:</i> In vitro, ex vivo and in vivo results.